Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

A 24-week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.

Tsubakihara Y, Akizawa T, Nangaku M, Onoue T, Yonekawa T, Matsushita H, Endo Y, Cobitz A.

Ther Apher Dial. 2019 Jul 15. doi: 10.1111/1744-9987.12962. [Epub ahead of print]

PMID:
31306555
2.

JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.

Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.

Eur J Pharmacol. 2019 Jul 10:172532. doi: 10.1016/j.ejphar.2019.172532. [Epub ahead of print]

PMID:
31301309
3.

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T.

Clin J Am Soc Nephrol. 2019 Jun 27. pii: CJN.14751218. doi: 10.2215/CJN.14751218. [Epub ahead of print]

PMID:
31248950
4.

Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?

Kanda E, Nangaku M.

Kidney Int. 2019 Jul;96(1):8-10. doi: 10.1016/j.kint.2019.04.005. No abstract available.

PMID:
31229049
5.

Light of dawn in Melbourne: SONAR and CREDENCE.

Nangaku M.

Kidney Int. 2019 Jul;96(1):2-4. doi: 10.1016/j.kint.2019.04.004. No abstract available.

PMID:
31229029
6.

Ascitic IL-10 concentration predicts prognosis of the patients undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy (CART).

Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, Miyagawa K.

Ther Apher Dial. 2019 Jun 3. doi: 10.1111/1744-9987.12863. [Epub ahead of print]

PMID:
31157953
7.

Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.

Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Maeda K, Miyazawa Y, Hirakata H.

Nephron. 2019 May 22:1-9. doi: 10.1159/000500487. [Epub ahead of print]

8.

Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation.

Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, Nangaku M, Abe M, Matsuhisa M, Kato S, Matsumoto T, Fukumoto S.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11418-11427. doi: 10.1073/pnas.1815166116. Epub 2019 May 16.

9.

Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.

Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N.

Endocr J. 2019 May 16. doi: 10.1507/endocrj.EJ19-0034. [Epub ahead of print]

10.

Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units: analysis of a nationwide administrative database in Japan, 2007-2016.

Miyamoto Y, Iwagami M, Aso S, Yasunaga H, Matsui H, Fushimi K, Hamasaki Y, Nangaku M, Doi K.

Crit Care. 2019 May 15;23(1):172. doi: 10.1186/s13054-019-2468-8.

11.

In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers.

Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K.

Nat Commun. 2019 Apr 24;10(1):1894. doi: 10.1038/s41467-019-09856-w.

12.

Usage Patterns of GlucoNote, a Self-Management Smartphone App, Based on ResearchKit for Patients With Type 2 Diabetes and Prediabetes.

Yamaguchi S, Waki K, Nannya Y, Nangaku M, Kadowaki T, Ohe K.

JMIR Mhealth Uhealth. 2019 Apr 24;7(4):e13204. doi: 10.2196/13204.

13.

Correction to: Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome.

Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M.

Clin Exp Nephrol. 2019 Jul;23(7):985. doi: 10.1007/s10157-019-01728-3.

14.

Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody.

Makita N, Ando T, Sato J, Manaka K, Mitani K, Kikuchi Y, Niwa T, Ootaki M, Takeba Y, Matsumoto N, Kawakami A, Ogawa T, Nangaku M, Iiri T.

JCI Insight. 2019 Apr 18;4(8). pii: 126449. doi: 10.1172/jci.insight.126449. eCollection 2019 Apr 18.

15.

Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.

Sakashita M, Tanaka T, Nangaku M.

Contrib Nephrol. 2019;198:112-123. doi: 10.1159/000496531. Epub 2019 Apr 16.

16.

Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury.

Hasegawa S, Susaki EA, Tanaka T, Komaba H, Wada T, Fukagawa M, Ueda HR, Nangaku M.

Kidney Int. 2019 Jul;96(1):129-138. doi: 10.1016/j.kint.2019.02.011. Epub 2019 Apr 9.

PMID:
30979565
17.

Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.

Saito H, Tanaka T, Sugahara M, Tanaka S, Fukui K, Wakashima T, Nangaku M.

Lab Invest. 2019 Apr 5. doi: 10.1038/s41374-019-0239-4. [Epub ahead of print]

PMID:
30952940
18.

Strategies for the Super-Aged Dialysis Population: Survival Benefits or Alternative Goals?

Sakurai S, Hanafusa N, Nomura T, Tsuchiya K, Nitta K, Nangaku M.

Blood Purif. 2019;47 Suppl 2:95-105. doi: 10.1159/000496660. Epub 2019 Apr 3.

PMID:
30943490
19.

Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome.

Takeuchi M, Sato J, Manaka K, Tanaka M, Matsui H, Sato Y, Kume H, Fukayama M, Iiri T, Nangaku M, Makita N.

Endocr J. 2019 Jun 28;66(6):547-554. doi: 10.1507/endocrj.EJ18-0563. Epub 2019 Mar 28.

20.

Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies.

Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T.

Clin Endocrinol (Oxf). 2019 Jul;91(1):195-200. doi: 10.1111/cen.13975. Epub 2019 Apr 11.

PMID:
30903705
21.

Recent advances in renal regeneration.

Hasegawa S, Tanaka T, Nangaku M.

F1000Res. 2019 Feb 25;8. pii: F1000 Faculty Rev-216. doi: 10.12688/f1000research.17127.1. eCollection 2019. Review.

22.

Regional variance in patterns of prescriptions for chronic kidney disease in Japan.

Inoue R, Nishi H, Tanaka T, Nangaku M.

Clin Exp Nephrol. 2019 Jun;23(6):859-864. doi: 10.1007/s10157-019-01720-x. Epub 2019 Mar 1.

PMID:
30820707
23.

Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.

Ebisawa K, Masamoto Y, Tokushige J, Nishi H, Honda K, Hinata M, Toyama K, Nangaku M, Kurokawa M.

Ann Hematol. 2019 Aug;98(8):1995-1997. doi: 10.1007/s00277-019-03616-y. Epub 2019 Feb 13. No abstract available.

PMID:
30761408
24.

Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.

Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H.

Cancer Sci. 2019 Apr;110(4):1464-1479. doi: 10.1111/cas.13968. Epub 2019 Mar 5.

25.

Endogenous Erythropoietin and Hepatic Dysfunction in Acute Kidney Injury Requiring Renal Replacement Therapy.

Matsuura R, Doi K, Komaru Y, Miyamoto Y, Yoshida T, Isegawa T, Yoshimoto K, Yamashita T, Noiri E, Nangaku M.

Nephron. 2019;142(1):10-16. doi: 10.1159/000496618. Epub 2019 Feb 1.

PMID:
30712038
26.

A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.

Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A, Hirakata H.

Am J Nephrol. 2019;49(2):165-174. doi: 10.1159/000496929. Epub 2019 Jan 30.

27.

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.

Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T.

Clin Exp Nephrol. 2019 Mar;23(3):435. doi: 10.1007/s10157-019-01694-w.

PMID:
30673934
28.

Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney.

Inoue T, Abe C, Kohro T, Tanaka S, Huang L, Yao J, Zheng S, Ye H, Inagi R, Stornetta RL, Rosin DL, Nangaku M, Wada Y, Okusa MD.

Kidney Int. 2019 Mar;95(3):563-576. doi: 10.1016/j.kint.2018.09.020. Epub 2019 Jan 19.

PMID:
30670317
29.

Regulatory roles of hypoxia-inducible, noncoding RNAs on mitochondrial dynamics during AKI.

Tanaka T, Nangaku M.

Kidney Int. 2019 Feb;95(2):252-253. doi: 10.1016/j.kint.2018.12.002. No abstract available.

PMID:
30665561
30.

ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis.

Jao TM, Nangaku M, Wu CH, Sugahara M, Saito H, Maekawa H, Ishimoto Y, Aoe M, Inoue T, Tanaka T, Staels B, Mori K, Inagi R.

Kidney Int. 2019 Mar;95(3):577-589. doi: 10.1016/j.kint.2018.09.023. Epub 2019 Jan 11.

PMID:
30639234
31.

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).

Kinoshita Y, Takashi Y, Ito N, Ikegawa S, Mano H, Ushiku T, Fukayama M, Nangaku M, Fukumoto S.

Bone Rep. 2018 Dec 31;10:100192. doi: 10.1016/j.bonr.2018.100192. eCollection 2019 Jun.

32.

Hepatocyte nuclear factor 4α regulates megalin expression in proximal tubular cells.

Sasaki S, Hara A, Sakaguchi M, Nangaku M, Inoue Y.

Biochem Biophys Rep. 2018 Dec 12;17:87-92. doi: 10.1016/j.bbrep.2018.11.010. eCollection 2019 Mar.

33.

Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway.

Hirakawa Y, Nangaku M.

Kidney Int. 2018 Dec;94(6):1038-1039. doi: 10.1016/j.kint.2018.10.004. No abstract available.

PMID:
30466558
34.

The Lasker Prize award 2018: histones "tail" the story.

Mimura I, Nangaku M.

Kidney Int. 2018 Dec;94(6):1032-1034. doi: 10.1016/j.kint.2018.10.005. No abstract available.

PMID:
30466557
35.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
36.

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.

Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, Koitka-Weber A.

J Diabetes Investig. 2019 May;10(3):760-770. doi: 10.1111/jdi.12971. Epub 2019 Jan 7.

37.

Pathogenesis of Atypical Hemolytic Uremic Syndrome.

Yoshida Y, Kato H, Ikeda Y, Nangaku M.

J Atheroscler Thromb. 2019 Feb 1;26(2):99-110. doi: 10.5551/jat.RV17026. Epub 2018 Nov 2. Review.

38.

Damage-associated molecular patterns in intensive care unit patients with acute liver injuries: A prospective cohort study.

Hayase N, Doi K, Hiruma T, Inokuchi R, Hamasaki Y, Noiri E, Nangaku M, Morimura N.

Medicine (Baltimore). 2018 Oct;97(41):e12780. doi: 10.1097/MD.0000000000012780.

39.

Nutcracker Syndrome with the Superimposition of Thin Basement Membrane Syndrome.

Hirakawa Y, Miura R, Sasaki Y, Yoshida Y, Mimura I, Katsura M, Shintani-Domoto Y, Ogawa M, Hayashi A, Nangaku M.

Intern Med. 2019 Feb 1;58(3):411-414. doi: 10.2169/internalmedicine.1433-18. Epub 2018 Sep 12.

40.
41.

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.

Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T.

Clin Exp Nephrol. 2019 Feb;23(2):231-243. doi: 10.1007/s10157-018-1632-9. Epub 2018 Sep 4. Erratum in: Clin Exp Nephrol. 2019 Jan 23;:.

42.

Extraperitoneal Placement of a Peritoneal Dialysis Catheter.

Nakamura Y, Kurata Y, Hamasaki Y, Nangaku M.

Intern Med. 2019 Jan 1;58(1):147-148. doi: 10.2169/internalmedicine.1396-18. Epub 2018 Aug 24. No abstract available.

43.

Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.

Hasegawa S, Tanaka T, Nangaku M.

Curr Opin Nephrol Hypertens. 2018 Sep;27(5):331-338. doi: 10.1097/MNH.0000000000000431. Review.

PMID:
30067604
44.

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.

Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.

45.

Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.

Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, Inagi R, Suematsu M, Nangaku M, Tanaka T.

Kidney Int. 2018 Nov;94(5):912-925. doi: 10.1016/j.kint.2018.04.025. Epub 2018 Jul 16.

PMID:
30021702
46.

Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Kanda E, Kashihara N, Matsushita K, Usui T, Okada H, Iseki K, Mikami K, Tanaka T, Wada T, Watada H, Ueki K, Nangaku M; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease.

Clin Exp Nephrol. 2018 Dec;22(6):1446-1475. doi: 10.1007/s10157-018-1615-x. No abstract available.

PMID:
30006871
47.

Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.

Toya T, Ogura M, Toyama K, Yoshimi A, Shinozaki-Ushiku A, Honda A, Honda K, Hosoya N, Murakami Y, Kawashima H, Nannya Y, Arai S, Nakamura F, Shinoda Y, Nangaku M, Miyagawa K, Fukayama M, Moriya-Saito A, Katayama I, Ogura T, Kurokawa M.

Haematologica. 2018 Nov;103(11):1815-1824. doi: 10.3324/haematol.2018.190728. Epub 2018 Jul 5.

48.

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.

Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.

49.

SLC4A4 compound heterozygous mutations in exon-intron boundary regions presenting with severe proximal renal tubular acidosis and extrarenal symptoms coexisting with Turner's syndrome: a case report.

Horita S, Simsek E, Simsek T, Yildirim N, Ishiura H, Nakamura M, Satoh N, Suzuki A, Tsukada H, Mizuno T, Seki G, Tsuji S, Nangaku M.

BMC Med Genet. 2018 Jun 18;19(1):103. doi: 10.1186/s12881-018-0612-y.

50.

Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response.

Anusornvongchai T, Nangaku M, Jao TM, Wu CH, Ishimoto Y, Maekawa H, Tanaka T, Shimizu A, Yamamoto M, Suzuki N, Sassa R, Inagi R.

Kidney Int. 2018 Sep;94(3):536-550. doi: 10.1016/j.kint.2018.03.011. Epub 2018 Jun 7.

Supplemental Content

Loading ...
Support Center